✦ LIBER ✦

Thirty-six-hour preoperative high-dose methotrexate infusion in patients with squamous carcinoma of the head and neck

✍ Scribed by Hande, K. R. ;Chretien, P. B. ;Elias, E. G. ;Goldberg, N. H. ;Brooks, A. E. ;Chabner, B. A.

Publisher: John Wiley and Sons
Year: 1979
Tongue: English
Weight: 330 KB
Volume: 6
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950060106

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty 36-hour infusions of high-dose methotrexate were given preoperatively to 10 patients with head and neck cancer. Plasma methotrexate levels of greater than 1 X 10(-5) M were maintained for 36 hours and declined with primary and secondary plasma half-lives of 1.7 and 9.2 hours following the end of the infusion. Toxicity of this infusion regimen was minimal (10% incidence of significant (WBC less than 2000/mm3) myelosuppression; no renal toxicity) and all patients underwent surgical resection within 3 weeks of therapy without obvious increase in operative complications. Four of ten patients responded to chemotherapy. Further comparison of the therapeutic efficacy of this prolonged preoperative infusion regimen with surgery alone or schedules employing conventional doses or 6-hour infusions of high-dose methotrexate appears warranted.

📜 SIMILAR VOLUMES

Methotrexate content in squamous cell ca

Methotrexate content in squamous cell carcinoma of the head and neck after low-dose methotrexate

✍ Schifeling, David J. ;George, Todd ;McGuirt, Fred ;Capizzi, Robert L. ;Kamen, Ba 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

## Abstract Eleven patients with squamous carcinoma of the head and neck who were scheduled for surgical resection or endoscopic biopsy of tumor received 15 mg/m^2^ of methotrexate (MTX). Samples of tumor, normal mucosa, and plasma were obtained at surgery or endoscopy, 18‐24 hours after the last M

Bleomycin infusion followed by cyclophos

Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck

✍ Terry F. Plasse; Takao Ohnuma; Sandra Brooks; Edwardo Saponaro; James F. Holland 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 301 KB 👁 1 views

Treatment of the neck in patients with s

Treatment of the neck in patients with squamous cell carcinoma of the head and neck

✍ Richard H. Jesse; Gilbert H. Fletcher 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB 👁 2 views

Immunoglobulin allotypes in patients wit

Immunoglobulin allotypes in patients with squamous cell carcinoma of the head and neck

✍ Theodorus Ockhuizen; Janardan P. Pandey; Robert W. Veltri; Myron Arlen; H. Hugh 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB 👁 2 views

Gm, A2m, and Km allotypic markers were examined in 40 Caucasian patients with squamous cell carcinomas of the head and neck. Serum IgA levels, the A2m(l) allotypic marker, and antibodies against IgAl, A2m(l), and A2m(2) were measured quantitatively. The frequency of Km(1) was found to be significant

Postoperative reduced dose of cisplatin

Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma

✍ Giovanni Franchin; Emilio Minatel; Doriano Politi; Carlo Gobitti; Renato Talamin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 2 views

Bimonthly high dose leucovorin and 5-flu

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma

✍ Karine Beerblock; Yves Rinaldi; Thierry André; Christophe Louvet; Eric Raymond; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

with low dose LV. Based on these reports, a first-line Phase II study was performed in 101 patients with advanced colorectal carcinoma who were given a bimonthly